<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02930434</url>
  </required_header>
  <id_info>
    <org_study_id>15-148</org_study_id>
    <secondary_id>RT_28-15</secondary_id>
    <nct_id>NCT02930434</nct_id>
  </id_info>
  <brief_title>Effects of Antarctic Environment on Vitamin D Status and Health Risk Biomarkers of Its Inhabitants</brief_title>
  <acronym>AntarD</acronym>
  <official_title>Effects of Antarctic Environment on Vitamin D Status and Health Risk Biomarkers of Its Inhabitants</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pontificia Universidad Catolica de Chile</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Fuerza Aérea de Chile</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Instituto Antártico Chileno</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Harvard Medical School</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Pontificia Universidad Catolica de Chile</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate vitamin D (VD) deficiency in the population of
      Chilean Antarctica and evaluate the efficacy and safety of VD supplementation to decrease VD
      deficiency and favorably influence biomarkers for bone, cardiovascular, and immune health
      risk in the inhabitants of Chilean Antarctica.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The present study consists of an initial cross-sectional evaluation of VD status and specific
      health biomarkers in inhabitants of Chilean Antarctica, followed by a randomized controlled
      trial evaluating two acceptable approaches of vitamin D supplementation (cholecalciferol 600
      IU daily vs. 25000 IU weekly) in Antarctic inhabitants.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2016</start_date>
  <completion_date type="Actual">March 1, 2018</completion_date>
  <primary_completion_date type="Actual">December 10, 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in serum 25-hydroxyvitamin D concentration</measure>
    <time_frame>at end of Antarctic residency or 1 year (90-365 days), whichever came first</time_frame>
    <description>In Antarctic inhabitants not supplemented with VD that exit Antarctica before start of RCT phase of study.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>sun exposure</measure>
    <time_frame>at 0, 6, 12 months of Antarctic residency</time_frame>
    <description>questionnaires</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>sleep pattern</measure>
    <time_frame>at 0, 6, 12 months of Antarctic residency</time_frame>
    <description>questionnaires</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>food intake of VD</measure>
    <time_frame>at 0, 6, 12 months of Antarctic residency</time_frame>
    <description>Food frequency questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>serum biomarkers for bone metabolism</measure>
    <time_frame>at baseline and every 3 months during supplementation (3,6,9,12 months) up to end of Antarctic residency or 1 year (90-365 days), whichever came first</time_frame>
    <description>intact PTH, calcium phosphorus, alkaline phosphatases, VD-binding protein</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>serum high-sensitivity C-reactive protein (hsCRP)</measure>
    <time_frame>at baseline and every 3 months during supplementation (3,6,9,12 months) up to end of Antarctic residency or 1 year (90-365 days), whichever came first</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>serum cathelicidin (LL-37) concentration</measure>
    <time_frame>at baseline and every 3 months during supplementation (3,6,9,12 months) up to end of Antarctic residency or 1 year (90-365 days), whichever came first</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">75</enrollment>
  <condition>Vitamin D Deficiency</condition>
  <arm_group>
    <arm_group_label>Standard daily vitamin D3</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Cholecalciferol 600 IU daily during one year or exit from Antarctica.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Higher weekly vitamin D3</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Cholecalciferol 25000 IU once weekly during one year or exit from Antarctica.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>cholecalciferol</intervention_name>
    <description>Administration of vitamin D3</description>
    <arm_group_label>Standard daily vitamin D3</arm_group_label>
    <arm_group_label>Higher weekly vitamin D3</arm_group_label>
    <other_name>Vitamin D3</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  population of all ages living in the Chilean Antarctic territory during at least 3
             months.

        Exclusion Criteria:

          -  acute or chronic renal disease

          -  hyper or hypocalcemia

          -  osteomalacia or Paget's disease of bone

          -  use of VD supplements or fish oil supplements in the past month in doses higher than
             400 IU daily

          -  treatment for known VD deficiency in the last 6 months

          -  UV phototherapy in the past month.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Arturo Borzutzky, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>School of Medicine, Pontificia Universidad Católica de Chile</affiliation>
  </overall_official>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 10, 2016</study_first_submitted>
  <study_first_submitted_qc>October 10, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 12, 2016</study_first_posted>
  <last_update_submitted>March 11, 2018</last_update_submitted>
  <last_update_submitted_qc>March 11, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 13, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Vitamin D</keyword>
  <keyword>cholecalciferol</keyword>
  <keyword>Antarctica</keyword>
  <keyword>Chile</keyword>
  <keyword>cathelicidin</keyword>
  <keyword>bone metabolism</keyword>
  <keyword>cardiovascular risk</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamin D Deficiency</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamins</mesh_term>
    <mesh_term>Vitamin D</mesh_term>
    <mesh_term>Ergocalciferols</mesh_term>
    <mesh_term>Cholecalciferol</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

